NCT06872892
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 46 versions: 46 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites reduced: 478 → 474 locations
- Minor Study sites revised (478)
- Minor Study sites revised (478)
- Publications expanded, about 63 words
- Minor Trial sites expanded: 471 → 478 locations
- Notable Eligibility criteria expanded, about 20 words
- Study sites: 470 to 471
- Secondary endpoints: details revised at 1 of 6 entries
Show 2 earlier versionsHide 2 earlier versions
- Minor Study sites: 471 to 470v41
- Minor Study sites: 470 to 471v40
- Notable Primary completion moved earlier from Sep 14, 2028 to Jun 15, 2027
- Study completion moved earlier from Oct 12, 2028 to Dec 20, 2027
- Study sites revised (470)
- Minor Trial sites reduced: 488 → 470 locationsv38
- Minor Trial sites reduced: 494 → 488 locationsv37
- Minor Study sites revised (494)v36
- Minor Study sites revised (494)v35
- Notable Eligibility criteria revised
- Site details revised at 9 of 494 sites
- Minor Site details revised at 27 of 494 sitesv33
- Minor Study sites: 495 to 494v32
- Minor Trial sites reduced: 498 → 495 locationsv31
- Minor Study sites: 497 to 498v30
- Minor Study sites revised (497)v29
- Minor Study sites: 498 to 497v28
- Minor Study sites: 499 to 498v27
- Minor Study sites: 503 to 499v26
- Minor Study sites: 501 to 503v25
- Minor Study sites: 505 to 501v24
- Minor Study sites: 511 to 505v23
- Minor Study sites: 508 to 511v22
- Minor Study sites: 512 to 508v21
- Notable Primary completion date: Jul 5, 2027 to Sep 14, 2028
- Study completion date: Aug 2, 2027 to Oct 12, 2028
- Notable Primary completion date: Sep 14, 2028 to Jul 5, 2027
- Study sites: 511 to 512
- Study completion date: Oct 12, 2028 to Aug 2, 2027
- Minor Study sites: 513 to 511v18
Notable Eligibility criteria expanded, about 34 wordsv17 Show 4 more changesShow less
- Primary endpoint revised
- Enrollment target: 1680 to 1755
- Secondary endpoints revised (6)
- Study title revised
- Minor Study sites: 511 to 513v16
- Minor Study sites revised (511)v15
- Minor Study sites: 503 to 511v14
- Minor Study sites: 485 to 503v13
- Minor Study sites: 477 to 485v12
- Minor Study sites revised (477)v11
- Minor Study sites: 462 to 477v10
- Minor Study sites: 441 to 462v9
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 414 to 441
- Start date changed from estimate of Jun 16, 2025 to Jun 9, 2025
- Minor Study sites: 394 to 414v7
- Minor Study sites: 384 to 394v6
- Minor Study sites: 375 to 384v5
- Minor Study sites: 321 to 375v4
- Minor Study sites: 301 to 321v3
- Minor Study sites: 0 to 301v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
Drugs: BI 1291583, Placebo matching BI 1291583
Sites
474 sites in 46 countries
United States 75, China 51, Japan 38, Germany 33, United Kingdom 23, Spain 21, South Korea 18, Italy 16, Australia 15, Argentina 12, France 11, Canada 10, Bulgaria 9, India 8, Mexico 8, Brazil 7, Latvia 7, New Zealand 7, Portugal 7, Malaysia 6, Netherlands 6, Poland 6, Taiwan 6, Denmark 5, Israel 5, Philippines 5, South Africa 5, Thailand 5, Belgium 4, Finland 4, Romania 4, Singapore 4, Czechia 3, Hungary 3, Ireland 3, Lithuania 3, Puerto Rico 3, Sweden 3, Austria 2, Chile 2, Croatia 2, Hong Kong 2, Kazakhstan 2, Slovakia 2, Switzerland 2, Turkey (Türkiye) 1